Inclusion Criteria:

          -  Diagnosis: Patients with histologically verified medulloblastoma with recurrence or
             progression involving anywhere in the brain and/or spine.

          -  Patient must have either measurable or evaluable tumor as assessed by MRI of the brain
             and total spine

          -  An implanted catheter in the fourth ventricle or posterior fossa tumor cavity attached
             to a ventricular access device or agreement to have one placed.

          -  A minimum of 7 days between last dose of systemic chemotherapy and/or radiation
             therapy and first infusion of chemotherapy into fourth ventricle

          -  Life expectancy of at least 12 weeks in the opinion of the principal investigator

          -  Lansky score of 50 or greater if ≤16 years of age or Karnofsky score of 50 or greater
             if > 16 years of age

          -  Existing neurological deficits must have been stable for a minimum of 1 week prior to
             study enrollment

          -  Patients must have recovered from the acute toxic effects of all prior anticancer
             chemotherapy

          -  Adequate bone marrow function defined by peripheral absolute neutrophil count (ANC) ≥
             500/µL, platelet count ≥ 50,000/µL (transfusion independent), and hemoglobin ≥ 9.0
             gm/dL (may receive red blood cells(RBC) transfusions)

          -  Patient or patient's legal representative, parent(s), or guardian able to provide
             written informed consent.

          -  Patient with prolonged QT interval on screening EKG will need cardiology consultation
             prior to enrollment

          -  Patients with abnormal liver function tests (ALT, Aspartate Aminotransferase(AST),or
             total bilirubin) will need gastroenterology consultation prior to enrollment

        Exclusion Criteria:

          -  Enrolled in another treatment protocol

          -  Has received another investigational or chemotherapy agent or radiation therapy within
             7 days prior to intraventricular chemotherapy infusions

          -  Evidence of untreated infection

          -  Pregnant or lactating women